The U.S. Food and Drug Administration (FDA) has granted fast track designation to muzastotug when used in combination with Keytruda (pembrolizumab) to treat adult patients with microsatellite stable ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback